Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Ionis Pharmaceuticals, Inc. - Common Stock (NQ:IONS)

83.64 +0.47 (+0.57%)

Streaming Delayed Price Updated: 10:27 AM EST, Jan 8, 2026 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	245,077
Open	83.17
Bid (Size)	83.58 (200)
Ask (Size)	83.69 (500)
Prev. Close	83.17
Today's Range	83.00 - 83.79
52wk Range	23.95 - 86.15
Shares Outstanding	141,797,854
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Ionis partner GSK announces positive topline results from B-Well 1 and B-Well 2 Phase 3 studies for bepirovirsen, a potential first-in-class medicine for chronic hepatitis B

January 07, 2026

From Ionis Pharmaceuticals, Inc.

Via Business Wire

Ionis to present at 44th Annual J.P. Morgan Healthcare Conference

January 06, 2026

From Ionis Pharmaceuticals, Inc.

Via Business Wire

Performance

YTD	+5.0%	+5.0%
1 Month	+2.6%	+2.6%
3 Month	+19.6%	+19.6%
6 Month	+95.3%	+95.3%
1 Year	+139.2%	+139.2%

More News

The RNAi Powerhouse: A Deep Dive into Alnylam Pharmaceuticals’ Path to the S&P 500

January 02, 2026

Via PredictStreet

Earnings Scheduled For October 29, 2025 ↗

October 29, 2025

Via Benzinga

Ionis receives U.S. FDA Breakthrough Therapy designation for zilganersen for Alexander disease (AxD)

December 02, 2025

From Ionis Pharmaceuticals, Inc.

Via Business Wire

Ionis receives U.S. FDA Breakthrough Therapy designation for olezarsen for severe hypertriglyceridemia (sHTG)

December 01, 2025

From Ionis Pharmaceuticals, Inc.

Via Business Wire

High Dose Regimen of Nusinersen Receives Positive CHMP Opinion for the Treatment of Spinal Muscular Atrophy

November 17, 2025

From Biogen Inc.

Via GlobeNewswire

Biogen Completes Acquisition of Alcyone Therapeutics

November 14, 2025

From Biogen Inc.

Via GlobeNewswire

DAWNZERA™ (donidalorsen) receives positive opinion from CHMP, recommended for approval in EU for hereditary angioedema (HAE)

November 14, 2025

From Ionis Pharmaceuticals, Inc.

Via Business Wire

Ionis Prices Convertible Notes Offering to Refinance 2026 Convertible Notes

November 13, 2025

From Ionis Pharmaceuticals, Inc.

Via Business Wire

Ionis to present at upcoming investor conferences

November 12, 2025

From Ionis Pharmaceuticals, Inc.

Via Business Wire

Metagenomi Prioritizes Hemophilia A Program, Lays Off 25% Workforce ↗

November 12, 2025

Via Benzinga

Ionis Announces Proposed Convertible Offering to Refinance 2026 Convertible Notes

November 11, 2025

From Ionis Pharmaceuticals, Inc.

Via Business Wire

Ionis Reports Substantial Drop In Acute Pancreatitis Events With Cholesterol Lowering Drug ↗

November 10, 2025

Via Benzinga

12 Health Care Stocks Moving In Monday's Pre-Market Session ↗

November 10, 2025

Via Benzinga

Monday.Com, Metsera, Profrac Holding And Other Big Stocks Moving Lower In Monday's Pre-Market Session ↗

November 10, 2025

Via Benzinga

Why Viasat Shares Are Trading Higher By Around 13%; Here Are 20 Stocks Moving Premarket ↗

November 10, 2025

Via Benzinga

Groundbreaking pivotal study results of olezarsen for severe hypertriglyceridemia (sHTG) presented as a late breaker at AHA Scientific Sessions

November 08, 2025

From Ionis Pharmaceuticals, Inc.

Via Business Wire

Intellia Therapeutics Crashes After A Patient In Its Pivotal Study Dies ↗

November 07, 2025

Via Investor's Business Daily

Ionis presents new data demonstrating long-term disease control with DAWNZERA™ (donidalorsen) at ACAAI 2025 Annual Meeting

November 06, 2025

From Ionis Pharmaceuticals, Inc.

Via Business Wire

Cathie Wood Goes All-In On Peter Thiel's Crypto Play Bullish With Back-To-Back Million-Dollar Buys ↗

November 04, 2025

Via Benzinga

Ionis (IONS) Q3 2025 Earnings Call Transcript ↗

October 30, 2025

Via The Motley Fool

Alnylam Stock Has Already Doubled In 2025. Why It Could Rocket Again On Earnings. ↗

October 30, 2025

Via Investor's Business Daily

Alphabet To Rally Around 22%? Here Are 10 Top Analyst Forecasts For Thursday ↗

October 30, 2025

Via Benzinga

Ionis reports third quarter 2025 financial results and highlights progress on key programs

October 29, 2025

From Ionis Pharmaceuticals, Inc.

Via Business Wire

Frequently Asked Questions

Is Ionis Pharmaceuticals, Inc. - Common Stock publicly traded?

Yes, Ionis Pharmaceuticals, Inc. - Common Stock is publicly traded.

What exchange does Ionis Pharmaceuticals, Inc. - Common Stock trade on?

Ionis Pharmaceuticals, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Ionis Pharmaceuticals, Inc. - Common Stock?

The ticker symbol for Ionis Pharmaceuticals, Inc. - Common Stock is IONS on the Nasdaq Stock Market

What is the current price of Ionis Pharmaceuticals, Inc. - Common Stock?

The current price of Ionis Pharmaceuticals, Inc. - Common Stock is 83.64

When was Ionis Pharmaceuticals, Inc. - Common Stock last traded?

The last trade of Ionis Pharmaceuticals, Inc. - Common Stock was at 01/08/26 10:27 AM ET

What is the market capitalization of Ionis Pharmaceuticals, Inc. - Common Stock?

The market capitalization of Ionis Pharmaceuticals, Inc. - Common Stock is 11.86B

How many shares of Ionis Pharmaceuticals, Inc. - Common Stock are outstanding?

Ionis Pharmaceuticals, Inc. - Common Stock has 12B shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.